Monitor for the appointment of a new independent director to fill the board vacancy and restore audit committee composition. The company has up to ~12 months to cure, but any delay in announcing a replacement could increase delisting concern. Watch for a subsequent 8-K announcing the appointment.
Price Chart
Executive Summary
SKYX Platforms Corp. filed an 8-K reporting that it fell out of compliance with Nasdaq's board independence and audit committee composition rules following the death of independent director Efrat L. Greenstein Brayer on September 26, 2026. The company received a cure period from Nasdaq that runs until the earlier of the next annual meeting or September 26, 2027 (or March 25, 2027 if the meeting is held before that date). This is a governance-related delisting notice with no immediate impact on listing, but failure to appoint a qualified independent director within the cure period could lead to delisting.
Key Facts
- Independent director Efrat L. Greenstein Brayer passed away on September 26, 2026.
- SKYX notified Nasdaq on September 28, 2026 that it no longer complies with Nasdaq Listing Rule 5605(b)(1) (majority independent board) and 5605(c)(2)(A) (audit committee of at least three members).
- Nasdaq granted a cure period expiring on the earlier of the next annual meeting or September 26, 2027; if the next annual meeting is before March 25, 2027, compliance must be shown by March 25, 2027.
- The company states it intends to take actions to regain compliance but provides no assurance of success.
- The filing states the non-compliance has no immediate effect on the Nasdaq listing, subject to compliance with listing rules.
Financial Impact
No financial figures provided in the filing. The primary risk is potential delisting if the board fails to regain compliance within the cure period, which could severely reduce liquidity and institutional ownership.
Risk Factors
- Failure to appoint a qualified independent director within the cure period could lead to Nasdaq delisting.
- Delisting would severely reduce liquidity and institutional ownership, potentially pressuring the stock price.
- The company's small market cap and potential difficulty attracting qualified independent directors may prolong the compliance gap.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-045379 |
| Document: 0001493152-26-045379-index-headers.html | 0001493152-26-045379 |
| Document: 0001493152-26-045379-index.html | 0001493152-26-045379 |
| Document: 0001493152-26-045379.txt | 0001493152-26-045379 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | EFFECT | $0.9000 | awaiting T+60 | — | $0.8329 (+7.46%) |
Oct 14, 2026 12d ago | S-3 | $1.01 | awaiting T+60 | — | $0.8329 (+17.53%) |
Oct 14, 2026 13d ago | 8-K | $1.04 | awaiting T+60 | — | $0.8329 (−19.91%) |
Oct 1, 2026 25d ago | 8-K | $1.18 | awaiting T+60 | — | $0.8329 (+29.42%) |
Sep 10, 2026 6w ago | 8-K | $1.32 | awaiting T+60 | — | $0.8329 (−36.90%) |
Sep 10, 2026 6w ago | Press Release | $1.32 | awaiting T+60 | — | $0.8329 (−36.90%) |
May 13, 2026 23w ago | DEFA14A | $1.14 $1.22 | ▲ +7.02% | ▲ +3.43% | $0.8329 (−26.94%) |
May 11, 2026 24w ago | 8-K | $1.14 $1.19 | ▲ +4.85% | ▲ +0.46% | $0.8329 (−26.62%) |
May 11, 2026 24w ago | Press Release | $1.14 $1.19 | ▲ +4.85% | ▲ +0.46% | $0.8329 (−26.62%) |
May 7, 2026 24w ago | Press Release | $1.46 $1.11 | ▼ −23.97% | ▼ −27.81% | $0.8329 (−42.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers